Fangzhou Raises HK$144.3 Million to Speed AI Chronic Disease Platform Expansion
I'm PortAI, I can summarize articles.
Fangzhou Inc. has raised HK$144.3 million through the placement of 45,181,000 shares at HK$3.32 each, with plans to use 90% of the proceeds for the development of its AI-powered chronic disease management platform. The remaining 10% will be allocated for working capital. The company aims to enhance its growth in digital health and AI services. Currently, the stock holds a Hold rating with a price target of HK$3.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments